Skip to main content
Top
Published in: Journal of Cancer Education 3/2015

01-09-2015

Physician Risk Assessment Knowledge Regarding BRCA Genetics Testing

Authors: Jason Cohn, William Blazey, David Tegay, Brian Harper, Sharon Koehler, Brookshield Laurent, Vivian Chan, Min-Kyung Jung, Bhuma Krishnamachari

Published in: Journal of Cancer Education | Issue 3/2015

Login to get access

Abstract

The study aim was to evaluate the association between genetics referrals, training in medical school, residency, or continuing medical education and physician knowledge of hereditary breast and ovarian cancer (HBOC). A survey of 55 questions was administered to 140 physicians evaluating knowledge and practice patterns regarding HBOC. Physicians with genetics training during residency were more likely to recognize that most instances of ovarian cancer are not hereditary (odds ratio (OR) = 3.16; 95 % confidence interval (CI) 1.32, 7.58). Physicians with continuing medical education (CME) training on genetics were more likely to identify that screening can be improved for those with a hereditary mutation (OR = 4.28; 95 % CI 1.32, 13.90). Primary care physicians who frequently referred for genetics were more likely to recognize that maternal history is not more important than paternal history (OR = 2.51; 95 % CI 1.11, 5.66), that screening can be improved for those with hereditary risk (OR = 4.06; 95 % CI 1.08, 15.22), and that females with a hereditary breast cancer risk would have different recommendations for screening than someone without this risk (OR = 4.91; 95 % CI 1.04, 23.25). Our data suggest that training and frequency of genetics referrals may be associated with knowledge of general risk assessment for HBOC.
Literature
1.
2.
go back to reference Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160(4):255–266CrossRefPubMed Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160(4):255–266CrossRefPubMed
3.
go back to reference Moyer VA (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160(4):271–281CrossRefPubMed Moyer VA (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160(4):271–281CrossRefPubMed
4.
5.
6.
go back to reference Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG, Magnetic Resonance Imaging Screening Study Group (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437CrossRefPubMed Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG, Magnetic Resonance Imaging Screening Study Group (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437CrossRefPubMed
7.
go back to reference Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarksi R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN, National Comprehensive Cancer Network (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw 8(5):562–594 Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarksi R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN, National Comprehensive Cancer Network (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw 8(5):562–594
8.
go back to reference King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant Breast and Bowel Project (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256CrossRefPubMed King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant Breast and Bowel Project (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256CrossRefPubMed
9.
go back to reference Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed
10.
go back to reference Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10(Suppl 1):S5–S9CrossRefPubMed Olopade OI, Artioli G (2004) Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10(Suppl 1):S5–S9CrossRefPubMed
11.
go back to reference Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Knowledge and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40(1):61–66CrossRefPubMed Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2011) Knowledge and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40(1):61–66CrossRefPubMed
12.
go back to reference Epplein M, Koon KP, Ramsey SD, Potter JD (2005) Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol 23(21):4713–4718CrossRefPubMed Epplein M, Koon KP, Ramsey SD, Potter JD (2005) Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol 23(21):4713–4718CrossRefPubMed
13.
go back to reference Vig HS, Armstrong J, Egleston BL, Mazar C, Toscano M, Bradbury AR, Daly MB, Meropol NJ (2009) Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 13(6):735–741PubMedCentralCrossRefPubMed Vig HS, Armstrong J, Egleston BL, Mazar C, Toscano M, Bradbury AR, Daly MB, Meropol NJ (2009) Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers 13(6):735–741PubMedCentralCrossRefPubMed
14.
go back to reference Dhar SU, Cooper HP, Wang T (2011) Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat 129(1):221–227PubMedCentralCrossRefPubMed Dhar SU, Cooper HP, Wang T (2011) Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat 129(1):221–227PubMedCentralCrossRefPubMed
15.
go back to reference National Comprehensive Cancer Network, Clinical practice guidelines in oncology, genetic/familial high-risk assessment: breast and ovarian 2010. Available at: www.nccn.org Accessed 7-24-12 National Comprehensive Cancer Network, Clinical practice guidelines in oncology, genetic/familial high-risk assessment: breast and ovarian 2010. Available at: www.​nccn.​org Accessed 7-24-12
16.
go back to reference Geier LJ, Mulvey TM, Weitzel JN (2009) ASCO 2009 educational book: practice management and information technology. American Society of Clinical Oncology; Clinical cancer genetics remains a specialized area: how do I get there from here? Geier LJ, Mulvey TM, Weitzel JN (2009) ASCO 2009 educational book: practice management and information technology. American Society of Clinical Oncology; Clinical cancer genetics remains a specialized area: how do I get there from here?
17.
go back to reference Vadaparampil ST, Wideroff L, Olson L, Viswanath K, Freedman AN (2005) Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A 135(1):41–46CrossRefPubMed Vadaparampil ST, Wideroff L, Olson L, Viswanath K, Freedman AN (2005) Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A 135(1):41–46CrossRefPubMed
18.
go back to reference Myers MF, Chang M, Jorgensen C, Whitworth W, Kassim S, Litch JA, Armstrong L, Bernhardt B, Faucett WA, Irwin D, Mouchawar J, Bradley LA (2006) Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices. Genet Med 8(6):361–370CrossRefPubMed Myers MF, Chang M, Jorgensen C, Whitworth W, Kassim S, Litch JA, Armstrong L, Bernhardt B, Faucett WA, Irwin D, Mouchawar J, Bradley LA (2006) Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices. Genet Med 8(6):361–370CrossRefPubMed
19.
go back to reference Blazer KR, MacDonald DJ, Culver JO, Huizenga CR, Morgan RJ, Uman GC, Weitzel JN (2011) Personalized cancer genetics training for personalized medicine: improving community-based health care through a genetically literate workforce. Genet Med 13(9):832–840PubMedCentralCrossRefPubMed Blazer KR, MacDonald DJ, Culver JO, Huizenga CR, Morgan RJ, Uman GC, Weitzel JN (2011) Personalized cancer genetics training for personalized medicine: improving community-based health care through a genetically literate workforce. Genet Med 13(9):832–840PubMedCentralCrossRefPubMed
20.
go back to reference Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE (2008) Physicians’ experiences with BRCA 1/2 testing in community settings. J Clin Oncol 26(35):5789–5796PubMedCentralCrossRefPubMed Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE (2008) Physicians’ experiences with BRCA 1/2 testing in community settings. J Clin Oncol 26(35):5789–5796PubMedCentralCrossRefPubMed
21.
go back to reference Pal T, Cragun D, Lewis C, Doty A, Rodriguez M, Radford C, Thompson Z, Kim J, Vadaparampil ST (2013) A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers 17(5):367–375PubMedCentralCrossRefPubMed Pal T, Cragun D, Lewis C, Doty A, Rodriguez M, Radford C, Thompson Z, Kim J, Vadaparampil ST (2013) A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers 17(5):367–375PubMedCentralCrossRefPubMed
22.
go back to reference Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN (2005) Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42(10):749–755PubMedCentralCrossRefPubMed Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN (2005) Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42(10):749–755PubMedCentralCrossRefPubMed
23.
go back to reference Gabram SG, Dougherty T, Albain KS (2009) Assessing breast cancer risk and providing treatment recommendations: immediate impact of an educational session. Breast J 15(Suppl 1):S39–S45CrossRefPubMed Gabram SG, Dougherty T, Albain KS (2009) Assessing breast cancer risk and providing treatment recommendations: immediate impact of an educational session. Breast J 15(Suppl 1):S39–S45CrossRefPubMed
24.
go back to reference Kliztman R, Chung W, Marder K, Shanmugham A, Chin LJ, Stark M, Leu CS, Appelbaum PS (2013) Attitudes and practices among internists concerning genetic testing. J Genet Couns 22(1):90–100CrossRef Kliztman R, Chung W, Marder K, Shanmugham A, Chin LJ, Stark M, Leu CS, Appelbaum PS (2013) Attitudes and practices among internists concerning genetic testing. J Genet Couns 22(1):90–100CrossRef
25.
go back to reference Prochniak CF, Martin LJ, Miller EM, Knapke SC (2012) Barriers to and motivations for physician referral of patients to cancer genetics clinics. J Genet Couns 21:305–325CrossRefPubMed Prochniak CF, Martin LJ, Miller EM, Knapke SC (2012) Barriers to and motivations for physician referral of patients to cancer genetics clinics. J Genet Couns 21:305–325CrossRefPubMed
Metadata
Title
Physician Risk Assessment Knowledge Regarding BRCA Genetics Testing
Authors
Jason Cohn
William Blazey
David Tegay
Brian Harper
Sharon Koehler
Brookshield Laurent
Vivian Chan
Min-Kyung Jung
Bhuma Krishnamachari
Publication date
01-09-2015
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 3/2015
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-014-0724-9

Other articles of this Issue 3/2015

Journal of Cancer Education 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine